emraclidine   Click here for help

GtoPdb Ligand ID: 13626

Synonyms: compound 21 [PMID: 38888621] | CVL-231 | CVL231 | PF-06852231 | PF06885190 [5]
Compound class: Synthetic organic
Comment: Emraclidine (CVL-231, formerly PF-06852231) is a brain-penetrant muscarinic acetylcholine M4 receptor positive allosteric modulator [2-3]. M4 receptor selectivity is achieved by targeting a unique allosteric domain rather than the orthosteric ligand binding site that is similar among the 5 receptor subtypes..
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

emraclidine is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 48.27
Molecular weight 390.4
XLogP 1.17
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1=C2CN(CC2=NC(=C1)C)C(=O)CC3CN(C3)C4=CC=NC(=C4)C(F)(F)F
Isomeric SMILES CC1=CC(=NC2=C1CN(C2)C(=O)CC3CN(C3)C4=CC(=NC=C4)C(F)(F)F)C
InChI InChI=1S/C20H21F3N4O/c1-12-5-13(2)25-17-11-27(10-16(12)17)19(28)6-14-8-26(9-14)15-3-4-24-18(7-15)20(21,22)23/h3-5,7,14H,6,8-11H2,1-2H3
InChI Key DTCZNKWBDTXEBS-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Emraclidine (CVL-231) is under evaluation as a treatment for psychosis, principally in schizophrenia and Alzheimer's disease dementia. However, in preliminary analyses emraclidine failed to meet the primary endpoint in the phase 2 EMPOWER-1 (NCT05227690) and EMPOWER-2 (NCT05227703) schizophrenia clinical trials [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05644977 A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease Phase 1 Interventional Cerevel Therapeutics, LLC
NCT05227690 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Phase 2 Interventional Cerevel Therapeutics, LLC
NCT04136873 A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia Phase 1 Interventional Cerevel Therapeutics, LLC 4
NCT05227703 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia Phase 2 Interventional Cerevel Therapeutics, LLC